Illumina Stock Performance
| ILMN Stock | USD 136.99 5.31 4.03% |
Illumina has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.64, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Illumina's returns are expected to increase less than the market. However, during the bear market, the loss of holding Illumina is expected to be smaller as well. Illumina right now retains a risk of 2.27%. Please check out Illumina semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Illumina will be following its current trending patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Illumina are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy primary indicators, Illumina is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.28 | Five Day Return (4.97) | Year To Date Return (0.27) | Ten Year Return (26.15) | All Time Return 600.84 |
Last Split Factor 1028:1000 | Last Split Date 2024-06-25 |
1 | Acquisition by Jacob Thaysen of 7426 shares of Illumina subject to Rule 16b-3 | 09/20/2024 |
2 | Disposition of 914 shares by Jacob Thaysen of Illumina at 140.66 subject to Rule 16b-3 | 10/04/2024 |
3 | Are You a Momentum Investor This 1 Stock Could Be the Perfect Pick | 10/24/2024 |
4 | Illumina earnings beat by 0.26, revenue was in line with estimates | 11/04/2024 |
5 | Illumina shares target raised, neutral rating on 3Q update | 11/06/2024 |
6 | Illumina signs MoU with PHASE to Advance Oncology Testing in the Greater Bay Area and Contribute to the Healthy China | 11/08/2024 |
7 | Morgan Stanley sets Illumina stock target, rates Equalweight on GRAIL resolution | 11/12/2024 |
8 | DNA Sequencing Market to Grow by USD 17.34 Billion , Driven by Rising NGS Adoption, AI-Powered Report Explores Market Evolution - Technavio | 11/13/2024 |
9 | Piper Sandler Cuts Illumina Price Target to 185.00 | 11/14/2024 |
10 | Whole Genome and Exome Sequencing Markets, 2033 - ResearchAndMarkets.com | 11/15/2024 |
11 | Is Illumina, Inc. the Best Immunotherapy Stock to Buy Now | 11/18/2024 |
12 | Myriad Genetics Announces Incorporation of its Proprietary HRD p | 11/20/2024 |
| Begin Period Cash Flow | 2 B |
Illumina |
Illumina Relative Risk vs. Return Landscape
If you would invest 13,139 in Illumina on August 23, 2024 and sell it today you would earn a total of 560.00 from holding Illumina or generate 4.26% return on investment over 90 days. Illumina is currently generating 0.0903% in daily expected returns and assumes 2.2661% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Illumina, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Illumina Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Illumina's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Illumina, and traders can use it to determine the average amount a Illumina's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0398
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ILMN | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.27 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Illumina is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Illumina by adding it to a well-diversified portfolio.
Illumina Fundamentals Growth
Illumina Stock prices reflect investors' perceptions of the future prospects and financial health of Illumina, and Illumina fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Illumina Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | 0.0262 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 23.15 B | ||||
| Shares Outstanding | 158.6 M | ||||
| Price To Earning | 49.12 X | ||||
| Price To Book | 10.08 X | ||||
| Price To Sales | 4.76 X | ||||
| Revenue | 4.5 B | ||||
| Gross Profit | 3.15 B | ||||
| EBITDA | (1.07 B) | ||||
| Net Income | (1.16 B) | ||||
| Cash And Equivalents | 2.01 B | ||||
| Cash Per Share | 6.62 X | ||||
| Total Debt | 2.26 B | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 0.93 X | ||||
| Book Value Per Share | 13.45 X | ||||
| Cash Flow From Operations | 478 M | ||||
| Earnings Per Share | (9.98) X | ||||
| Market Capitalization | 20.88 B | ||||
| Total Asset | 10.11 B | ||||
| Retained Earnings | (19 M) | ||||
| Working Capital | 1.04 B | ||||
| Current Asset | 2.1 B | ||||
| Current Liabilities | 610.49 M | ||||
About Illumina Performance
By examining Illumina's fundamental ratios, stakeholders can obtain critical insights into Illumina's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Illumina is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 121.74 | 175.11 | |
| Return On Tangible Assets | (0.25) | (0.24) | |
| Return On Capital Employed | (0.13) | (0.12) | |
| Return On Assets | (0.11) | (0.11) | |
| Return On Equity | (0.20) | (0.19) |
Things to note about Illumina performance evaluation
Checking the ongoing alerts about Illumina for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Illumina help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Illumina currently holds 2.26 B in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Illumina has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Illumina's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 4.5 B. Net Loss for the year was (1.16 B) with profit before overhead, payroll, taxes, and interest of 3.15 B. | |
| Over 95.0% of Illumina shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Myriad Genetics Announces Incorporation of its Proprietary HRD p |
- Analyzing Illumina's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Illumina's stock is overvalued or undervalued compared to its peers.
- Examining Illumina's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Illumina's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Illumina's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Illumina's stock. These opinions can provide insight into Illumina's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (9.98) | Revenue Per Share 27.654 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0262 |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.